HUTCHMED’s Post

Here are some insights indicating upcoming preclinical trials that Zymewire found this week 🤙 1️⃣ Accent Therapeutics, Inc. : Planning to initiate IND-enabling studies for KIF18A in the first half of 2024, a treatment to be used in several different cancer indications. 2️⃣ Cereno Scientific: Initiating clinical Phase I study with drug candidate CS014 and pursuing pre-clinical development program with drug candidate CS585 for the prevention of thrombosis. 3️⃣ Recbio: Plan to complete preclinical studies of REC625, a novel adjuvanted recombinant respiratory syncytial virus vaccine in 2024 4️⃣ ImmunoScape: Focused on next-generation T Cell receptor (TCR)-based immunotherapies. Have multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. 5️⃣ Entera Bio Ltd.: Announces robust pharmacokinetic data for first-in-class oral GLP-2 peptide tablet treatment for patients with Short Bowel Syndrome. Planning to advance the program to assess pharmacologic effects in vivo. #preclinical #SOT #founditonzymewire #noveltherapy

We are pleased to announce the approval in China of our lead drug, Olverembatinib for Chronic Myeloid Leukemia (CML) patients resistant to or intolerant of first- and second-generation Tyrosine Kinase Inhibitors (TKIs). Even though TKIs have revolutionized the management of CML, approx 40% of the patients develop resistance/intolerance to these drugs and lack effective treatment options. This expansion of Olverambatinib’s indications provides a viable therapeutic option to the patients in China. We continue to investigate Olverembatinib’s therapeutic potential in multiple clinical trials across the globe. #leukemia #cml #ash #cancer #cancerresearch #drugdevelopment

THE TOP 10 SMALL MOLECULES OF JANUARY 2024 From a small molecule (fluorinated!), non-opioid, for the treatment of pain (NaV1.8, by #Latigo Biotherapeutics), which competes with Vertex's #VX-548. In the top ten there is a potential first-class pan-PKC inhibitor (Ph. II/III) indicated in the treatment of #uveal melanoma. Also an antibiotic effective against antibiotic-resistant strains, the macrocyclic peptide #zosurabalpin works with a novel mechanism of action. Effective in carbapenem-resistant Acinetobacter baumannii infections. More information below: https://lnkd.in/eH3UwEkd c0-%5BLIST_EMAIL_ID%5D

Today, at the AAIC 2024 conference, Dr. Madiha Derouazi, CSO of AC Immune, presented data from our novel therapeutic morADC – Morphomer® Antibody Drug Conjugate - for the first time. This powerful new technology synergistically combines AC Immune’s industry-leading SupraAntigen® (biologics) and Morphomer® (small molecule) platforms. morADC are designed for CNS applications and enable single or dual-targeting strategies (e.g. an anti-Abeta antibody combined with an anti-Tau small molecule) to deliver combination therapy in a single therapeutic agent. In addition, conjugation of brain-penetrant Morphomers with a monoclonal antibody can multiply antibody brain exposure. Find out more about this groundbreaking progress in our mission to pioneer precision medicine for neurodegenerative diseases: https://lnkd.in/eThpD5KD #alzheimers #prevention #PrecisionMedicine #AAIC24

We are investing up to $8.5 million in additional funds in SpliSense to conduct a Phase 2 clinical trial to test its inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T. Splicing mutations disrupt the production of normal cystic fibrosis transmembrane conductance regulator (CFTR) RNA, resulting in dysfunctional CFTR proteins. SpliSense’s drug would work by binding to the RNA molecule in lung cells and correcting the instructions to create healthy, full-length CFTR proteins, helping restore the proper balance of salt and fluids in the lungs of people with CF. If the clinical trial is successful, it could validate other similar therapeutic approaches in SpliSense's pipeline that address rare CF mutations.

Overcoming BTK mutations that confer resistance across covalent and noncovalent BTK inhibitors. Disrupting the scaffold function of BTK by NX-2127, a potent BTK degrader, a drug that could degrade both wild-type and mutant forms of the BTK protein. In a phase 1 clinical trial, NX-2127 showed promising responses for patients with relapsed and refractory CLL, independently of mutant BTK functional category and may provide a means of treating those tumors resistant to current BTK inhibitors.

Targeted pharmacological inhibition of cell cycle regulators has long been considered a promising anti-cancer strategy. Recent advances in our understanding of the molecular basis of cell cycle disruption and the mechanisms of resistance have reignited interest in blocking specific components of the cell cycle machinery. Check out this article to learn about the latest developments in the field. #cancerresearch #pharmacology #cellcycleinhibition https://lnkd.in/ecBEd-52

Mustang Bio announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application of MB-109 for the treatment of recurrent glioblastoma (GBM) and high-grade astrocytoma. Mustang is planning a Phase 1 study to assess the safety, tolerability and efficacy of MB-109 in patients with GBM and high-grade astrocytoma and is expected to begin enrolling patients in 2024. MB-109 is a novel combination of MB-101 (City of Hope-developed IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (Nationwide Children’s Hospital-developed HSV-1 oncolytic virus]. Read more:

This would be helpful for sequential approach.

A 1990s Abbott Candidate Revived by a Biotech for Renal Health | https://lnkd.in/g-CGsqrR Atrasentan, an ETA receptor antagonist discovered by Abbott (AbbVie) in the 1990s, was initially researched for its potential in treating prostate cancer. AbbVie later licensed the drug to Chinook Therapeutics, a Novartis Company, which discovered its efficacy in treating kidney diseases. This led to Novartis' unexpected $3.2B acquisition of Chinook, stunning an investment firm that bet against Chinook’s survival through short selling. Novartis recently presented results from a pre-specified interim analysis of the Ph. III ALIGN study on atrasentan in patients with IgA nephropathy (IgAN) at the 2024 European Renal Association (ERA) Congress, and submission to the FDA for the accelerated approval is anticipated in 2024. Atrasentan provides an intriguing story on the challenges in drug discovery for kidney diseases, the importance and interpretation of biomarkers, and the winding decades-long path drugs can take from initial therapeutic hypothesis to a suitable clinical indication. Full article: https://lnkd.in/g-CGsqrR